Muneer A. Satter Acquires 60,000 Shares of Aerpio Pharmaceuticals Inc (ARPO) Stock

Share on StockTwits

Aerpio Pharmaceuticals Inc (OTCMKTS:ARPO) Director Muneer A. Satter purchased 60,000 shares of the stock in a transaction dated Thursday, December 6th. The stock was acquired at an average cost of $2.09 per share, with a total value of $125,400.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

OTCMKTS:ARPO opened at $2.08 on Friday. Aerpio Pharmaceuticals Inc has a 52 week low of $1.75 and a 52 week high of $5.50.

Aerpio Pharmaceuticals (OTCMKTS:ARPO) last posted its earnings results on Wednesday, November 7th. The company reported $0.28 EPS for the quarter, missing the Zacks’ consensus estimate of $0.34 by ($0.06). The company had revenue of $18.82 million for the quarter, compared to the consensus estimate of $18.67 million.

A number of large investors have recently bought and sold shares of ARPO. Orbimed Advisors LLC purchased a new stake in Aerpio Pharmaceuticals during the second quarter valued at approximately $21,555,000. Vanguard Group Inc. purchased a new stake in Aerpio Pharmaceuticals during the third quarter valued at approximately $3,331,000. FMR LLC purchased a new stake in Aerpio Pharmaceuticals during the second quarter valued at approximately $3,648,000. Nexthera Capital LP purchased a new stake in Aerpio Pharmaceuticals during the second quarter valued at approximately $1,240,000. Finally, Millennium Management LLC purchased a new stake in Aerpio Pharmaceuticals during the second quarter valued at approximately $934,000. 0.37% of the stock is owned by institutional investors.

A number of equities research analysts recently commented on ARPO shares. HC Wainwright set a $9.00 target price on shares of Aerpio Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 15th. Zacks Investment Research cut shares of Aerpio Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 16th. Finally, Guggenheim started coverage on shares of Aerpio Pharmaceuticals in a research report on Wednesday, September 19th. They set a “buy” rating and a $10.00 target price for the company.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://baseballnewssource.com/2018/12/08/muneer-a-satter-acquires-60000-shares-of-aerpio-pharmaceuticals-inc-arpo-stock/3064978.html.

About Aerpio Pharmaceuticals

Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema.

See Also: Average Daily Trade Volume – What You Need to Know

Receive News & Ratings for Aerpio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerpio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.